Rajesh Khatri - Kilitch Drugs General Administration
| KILITCH Stock | 362.35 6.15 1.73% |
Executive
Rajesh Khatri is General Administration of Kilitch Drugs Limited
| Age | 50 |
| Address | 37/39, Ujagar Industrial Estate, Mumbai, India, 400088 |
| Phone | 91 22 6121 4100 |
| Web | https://www.kilitch.com |
Kilitch Drugs Management Efficiency
The company has return on total asset (ROA) of 0.0566 % which means that it generated a profit of $0.0566 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0832 %, meaning that it generated $0.0832 on every $100 dollars invested by stockholders. Kilitch Drugs' management efficiency ratios could be used to measure how well Kilitch Drugs manages its routine affairs as well as how well it operates its assets and liabilities. The current Total Assets is estimated to decrease to about 1.7 B. The current Non Current Assets Total is estimated to decrease to about 749.4 MSimilar Executives
| Showing other executives | EXECUTIVE Age | ||
| Sindoori Reddy | Apollo Hospitals Enterprise | 43 | |
| Dasaratha Reddy | Apollo Hospitals Enterprise | 70 | |
| Bhanvesh Naik | Mangalam Drugs And | 46 | |
| P Jain | Transport of | 62 | |
| Shobana Kamineni | Apollo Hospitals Enterprise | 64 | |
| Pramod Jain | Transport of | 63 | |
| S Krishnan | Apollo Hospitals Enterprise | 56 | |
| Sadasivam | Healthcare Global Enterprises | 68 | |
| Ruby Ritolia | Healthcare Global Enterprises | N/A | |
| Anurag Kalra | Fortis Healthcare Limited | N/A | |
| Madan Sampath | Healthcare Global Enterprises | N/A | |
| Vivek Goyal | Fortis Healthcare Limited | N/A | |
| Srinivasa Raghavan | Healthcare Global Enterprises | 59 | |
| Krishnan Akhileswaran | Apollo Hospitals Enterprise | 50 | |
| V Venkataramanan | Healthcare Global Enterprises | 51 | |
| Sunu Abey | Healthcare Global Enterprises | N/A | |
| Ishwar Sigar | Transport of | 56 | |
| Surinder Dang | Healthcare Global Enterprises | 58 | |
| Bipin Kumar | Fortis Healthcare Limited | N/A | |
| Archana Pandey | Transport of | N/A | |
| Rakesh Srivastava | Mangalam Drugs And | 51 | |
Management Performance
| Return On Equity | 0.0832 | ||||
| Return On Asset | 0.0566 |
Kilitch Drugs Limited Leadership Team
Elected by the shareholders, the Kilitch Drugs' board of directors comprises two types of representatives: Kilitch Drugs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kilitch. The board's role is to monitor Kilitch Drugs' management team and ensure that shareholders' interests are well served. Kilitch Drugs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kilitch Drugs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mukund Mehta, Executive MD | ||
| Bhavin BPharm, Wholetime Director | ||
| LLB BCom, Executive MD | ||
| Sunil Jain, Chief Officer | ||
| Mira Mehta, Managing Director | ||
| Pushpa Nyoupane, Company Officer | ||
| Rajesh Khatri, General Administration | ||
| Tajouddin Ansari, VPMarketing Operation |
Kilitch Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kilitch Drugs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0832 | ||||
| Return On Asset | 0.0566 | ||||
| Profit Margin | 0.11 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 5.38 B | ||||
| Shares Outstanding | 16.08 M | ||||
| Shares Owned By Insiders | 75.15 % | ||||
| Price To Book | 3.08 X | ||||
| Price To Sales | 3.13 X | ||||
| Revenue | 1.54 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Other Information on Investing in Kilitch Stock
Kilitch Drugs financial ratios help investors to determine whether Kilitch Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kilitch with respect to the benefits of owning Kilitch Drugs security.